Author + information
- Received April 20, 2020
- Revision received April 27, 2020
- Accepted April 30, 2020
- Published online July 15, 2020.
- Nadia Castaldo, MDa,
- Alberto Aimo, MDb,c,∗ ( )(, )
- Vincenzo Castiglione, MDb,c,
- Cristiano Padalino, MDa,
- Michele Emdin, MD, PhDb,d and
- Carlo Tascini, MD, PhDa
- aAzienda Sanitaria Integrata del Friuli Centrale, Udine, Italy
- bInstitute of Life Science, Scuola Sant’Anna Pisa, Pisa, Italy
- cCardiology Division, University Hospital of Pisa, Pisa, Italy
- dCardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy
- ↵∗Address for correspondence:
Dr. Alberto Aimo, Cardiology Division, University Hospital of Pisa, and Institute of Life Sciences, Scuola Superiore Sant’Anna, Piazza Martiri della Libertà, 33, 56124 Pisa, Italy.
There is an urgent need for effective treatments for coronavirus disease-2019 (COVID-19). Amiodarone, like hydroxychloroquine, exerts antiviral actions by interfering with endocytosis and viral replication. Here, to our knowledge, we report the first case of a patient affected by respiratory failure related to COVID-19 who recovered after only supportive measures and a short amiodarone course. (Level of Difficulty: Beginner.)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.
- Received April 20, 2020.
- Revision received April 27, 2020.
- Accepted April 30, 2020.
- 2020 The Authors